New Allegra® Anti-Itch Cream Introduced by Sanofi's Chattem

         New Allegra® Anti-Itch Cream Introduced by Sanofi's Chattem

Over-the-Counter Allergy Brand Now Offers Topical Relief for Itchy, Dry Skin
Just in Time for Summer

PR Newswire

BRIDGEWATER, N.J., April 11, 2013

BRIDGEWATER, N.J., April 11, 2013 /PRNewswire/ --Allegra Anti-Itch Cooling
Relief Cream and Allegra Anti-Itch Intensive Relief Cream are now available in
drug, grocery and mass merchandiser stores nationwide. Chattem, Inc., the
Consumer Healthcare Division of Sanofi US and the makers of Allegra Allergy,
introduced the Anti-Itch Creams to its family of products to help provide itch
relief from reactions to skin irritations.

Allegra Anti-Itch Cooling Relief provides fast cooling relief for hot, itchy
skin while Allegra Anti-Itch Intensive Relief provides moisturizing relief for
itchy, dry and irritated skin. Both products provide temporary relief from the
pain and itching associated with insect bites, minor skin irritations,
sunburn, rashes due to poison ivy, poison oak or poison sumac, and minor cuts
and scrapes. They also temporarily protect and help relieve chapped or cracked

"We identified an opportunity in the topical anti-itch category and leveraged
our experience with Allegra Allergy to introduce a new product for common skin
irritations that not only helps stop the itch but also provides a moisturizing
benefit," said John Stroud, Executive Vice President, Marketing, Chattem.

Itchy skin can be triggered by a chemical in a person's body called histamine.
Histamine is a person's immune system reacting to an irritant, like an insect
bite or poison ivy. Allegra Anti-Itch Cream acts as an antihistamine, going
beneath the surface of the skin to stop the itch at its source. In addition,
the moisturizers and vitamins A, C and E in Allegra Anti-Itch Cream help
soothe the skin, and the allantoin protects the skin while it gets back to
normal after scratching.

Allegra Anti-Itch Cream is indicated for adults and children ages 2 and up.
The suggested retail price is $4.99-$6.99. For additional information on the
Allegra family of products, please visit Follow us on
Facebook and Twitter.

About Allegra^®
Allegra Allergy has been providing allergy sufferers with relief of symptoms
from indoor and outdoor allergies for more than 15 years. The Allegra family
of products is available without a prescription in drug, grocery, mass
merchandiser and club stores nationwide.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US, also referred to as sanofi-aventis
U.S. LLC. For more information on Sanofi US, please visit call 1-800-981-2491.

About  Chattem
In March 2010, Chattem, Inc. became a wholly-owned subsidiary of the
sanofi-aventis Group, as the consumer healthcare division of Sanofi US.
Chattem is more than 130 years old and is a leading manufacturer and marketer
of branded consumer healthcare products, toiletries and dietary supplements
across niche market segments in the United States. For more information,
please visit Chattem's website at

Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group's
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.


Contact: Media Relations, Rachel Ferrand, 908 981 6673,
Press spacebar to pause and continue. Press esc to stop.